{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T12:15:54Z","timestamp":1786968954444,"version":"build-2736575974"},"reference-count":66,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,13]],"date-time":"2019-12-13T00:00:00Z","timestamp":1576195200000},"content-version":"vor","delay-in-days":530,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","journals.elsevierhealth.com","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Pathology"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1016\/j.ajpath.2018.03.018","type":"journal-article","created":{"date-parts":[[2018,6,19]],"date-time":"2018-06-19T03:43:48Z","timestamp":1529379828000},"page":"1608-1624","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Beneficial Effects of the Peroxisome Proliferator-Activated Receptor \u03b1\/\u03b3 Agonist Aleglitazar on Progressive Hepatic and Splanchnic Abnormalities in Cirrhotic Rats with Portal Hypertension"],"prefix":"10.1016","volume":"188","author":[{"given":"Hung-Cheng","family":"Tsai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tzu-Hao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Chang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6685-8259","authenticated-orcid":false,"given":"Shiang-Fen","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren-Shyan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-Ying","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun-Cheng","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8088-6320","authenticated-orcid":false,"given":"Kuei-Chuan","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5241-5425","authenticated-orcid":false,"given":"Yi-Hsiang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Chih","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han-Chieh","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajpath.2018.03.018_bib1","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0168-8278(00)80422-5","article-title":"Complication of cirrhosis, I: portal hypertension","volume":"32","author":"Bosch","year":"2000","journal-title":"J Hepatol"},{"key":"10.1016\/j.ajpath.2018.03.018_bib2","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1002\/hep.25534","article-title":"Hepatic endothelin-1 and endocannabinoids-dependent effects of hyperleptinemia in nonalcoholic steatohepatitis-cirrhotic rats","volume":"55","author":"Yang","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.ajpath.2018.03.018_bib3","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1136\/gut.2005.081059","article-title":"Intrahepatic upregulation of RhoA and Rho-kinase signalling contributes to increased hepatic vascular resistance in rats with secondary biliary cirrhosis","volume":"55","author":"Zhou","year":"2006","journal-title":"Gut"},{"key":"10.1016\/j.ajpath.2018.03.018_bib4","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.jhep.2010.07.004","article-title":"Intrahepatic angiogenesis and sinusoidal remodeling in chronic liver disease: new targets for the treatment of portal hypertension?","volume":"53","author":"Thabut","year":"2010","journal-title":"J Hepatol"},{"key":"10.1016\/j.ajpath.2018.03.018_bib5","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1002\/hep.22170","article-title":"Hemodynamic effects of urotensin II and its specific receptor antagonist palosuran in cirrhotic rats","volume":"47","author":"Trebicka","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.ajpath.2018.03.018_bib6","doi-asserted-by":"crossref","first-page":"G1010","DOI":"10.1152\/ajpgi.00350.2010","article-title":"Increased contractility of hepatic stellate cells in cirrhosis is mediated by enhanced Ca2+-dependent and Ca2+-sensitization pathways","volume":"300","author":"Iizuka","year":"2011","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.ajpath.2018.03.018_bib7","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1002\/hep.22758","article-title":"Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats","volume":"49","author":"Mejias","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.ajpath.2018.03.018_bib8","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.jhep.2006.11.018","article-title":"Bacterial translocation is down-regulated by anti-TNF-\u03b1 monocloncal antibody administration in rats with cirrhosis and ascites","volume":"46","author":"Natarajan","year":"2007","journal-title":"J Hepatol"},{"key":"10.1016\/j.ajpath.2018.03.018_bib9","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/hep.21097","article-title":"Intestinal mucosal alterations in rats with carbon tetrachloride induced cirrhosis: changes in glycosylation and luminal bacteria","volume":"43","author":"Natarajan","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.ajpath.2018.03.018_bib10","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1002\/hep.23775","article-title":"Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites","volume":"52","author":"Serst\u00e9","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.ajpath.2018.03.018_bib11","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1124\/jpet.106.104992","article-title":"Peroxisome proliferator-activated receptor alpha activation-mediated regulation of endothelin-1 production via nitric oxide and protein kinase C signaling pathways in piglet cerebral microvascular endothelial cell culture","volume":"320","author":"Yakubu","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.ajpath.2018.03.018_bib12","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.pharmthera.2005.08.007","article-title":"Peroxisome proliferator-activated receptors and inflammation","volume":"110","author":"Moraes","year":"2006","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.ajpath.2018.03.018_bib13","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s10456-008-9118-0","article-title":"PPAR gamma ligands, rosiglitazone and pioglitazone, inhibit bFGF- and VEGF-mediated angiogenesis","volume":"11","author":"Aljada","year":"2008","journal-title":"Angiogenesis"},{"key":"10.1016\/j.ajpath.2018.03.018_bib14","doi-asserted-by":"crossref","first-page":"S162","DOI":"10.2337\/dcS13-2003","article-title":"In\u00a0vivo actions of peroxisome proliferator\u2013activated receptors glycemic control, insulin sensitivity, and insulin secretion","volume":"36","author":"Eldor","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ajpath.2018.03.018_bib15","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.cmet.2007.06.010","article-title":"PPARgamma activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties","volume":"6","author":"Bouhlel","year":"2007","journal-title":"Cell Metab"},{"key":"10.1016\/j.ajpath.2018.03.018_bib16","doi-asserted-by":"crossref","first-page":"470","DOI":"10.4254\/wjh.v5.i9.470","article-title":"Current role of fenofibrate in the prevention and management of non-alcoholic fatty liver disease","volume":"5","author":"Kostapanos","year":"2013","journal-title":"World J Hepatol"},{"key":"10.1016\/j.ajpath.2018.03.018_bib17","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.clinre.2015.02.011","article-title":"Fenofibrate is effective adjunctive therapy in the treatment of primary biliary cirrhosis: a meta-analysis","volume":"39","author":"Grigorian","year":"2015","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10.1016\/j.ajpath.2018.03.018_bib18","doi-asserted-by":"crossref","first-page":"305","DOI":"10.7326\/M15-1774","article-title":"Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial","volume":"165","author":"Cusi","year":"2016","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ajpath.2018.03.018_bib19","first-page":"31424","article-title":"Response to pioglitazone in patients with nonalcoholic steatohepatitis with vs without type 2 diabetes","volume":"S1542-3565","author":"Bril","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.ajpath.2018.03.018_bib20","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.jhep.2011.12.008","article-title":"PPAR\u03b1 activation improves endothelial dysfunction and reduces fibrosis and portal pressure in cirrhotic rats","volume":"56","author":"Rodr\u00edguez-Vilarrupla","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.ajpath.2018.03.018_bib21","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.jhep.2014.01.025","article-title":"Pioglitazone decreases portosystemic shunting by modulating inflammation and angiogenesis in cirrhotic and non-cirrhotic portal hypertensive rats","volume":"60","author":"Schwabl","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.ajpath.2018.03.018_bib22","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.amjmed.2007.03.025","article-title":"Impact of diabetes on the severity of liver disease","volume":"120","author":"Hickman","year":"2007","journal-title":"Am J Med"},{"key":"10.1016\/j.ajpath.2018.03.018_bib23","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s10238-013-0262-5","article-title":"The effect of the severity of liver cirrhosis on the level of lipids and lipoproteins","volume":"14","author":"Chrostek","year":"2014","journal-title":"Clin Exp Med"},{"key":"10.1016\/j.ajpath.2018.03.018_bib24","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","article-title":"Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial","volume":"366","author":"Keech","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.ajpath.2018.03.018_bib25","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","article-title":"Effects of combination lipid therapy in type 2 diabetes mellitus","volume":"362","author":"Ginsberg","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajpath.2018.03.018_bib26","first-page":"41","article-title":"Fenofibrate increases blood creatinine, but does not change the glomerular filtration rate in patients with mild renal insufficiency","volume":"20","author":"Hottelart","year":"1999","journal-title":"Nephrologie"},{"key":"10.1016\/j.ajpath.2018.03.018_bib27","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.coph.2006.06.009","article-title":"PPARalpha and PPARgamma dual agonists for the treatment of type 2 diabetes and the metabolic syndrome","volume":"6","author":"Fi\u00e9vet","year":"2006","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.ajpath.2018.03.018_bib28","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1161\/01.ATV.0000242904.34700.66","article-title":"Dual PPARalpha\/gamma agonist tesaglitazar reduces atherosclerosis in insulin-resistant and hypercholesterolemic ApoE*3 Leiden mice","volume":"26","author":"Zadelaar","year":"2006","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.ajpath.2018.03.018_bib29","doi-asserted-by":"crossref","first-page":"R51","DOI":"10.1186\/ar4211","article-title":"Anti-inflammatory properties of a dual PPARgamma\/alpha agonist muraglitazar in in\u00a0vitro and in\u00a0vivo models","volume":"15","author":"Paukkeri","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.ajpath.2018.03.018_bib30","first-page":"A10854","article-title":"Aleglitazar, a balanced dual PPAR alpha\/gamma agonist, decreases lipolysis and cytokine production in a cellular model of inflamed human adipose tissue","volume":"122","author":"Dzyakanchuk","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.ajpath.2018.03.018_bib31","first-page":"4596","article-title":"The dual PPAR-\u03b1\/\u03b3 agonist aleglitazar attenuates retinopathy in streptozotocin diabetic rats","volume":"54","author":"de la Flor","year":"2013","journal-title":"Invest Ophth Vis Sci"},{"key":"10.1016\/j.ajpath.2018.03.018_bib32","series-title":"Guide for the Care and Use of Laboratory Animals: Eighth Edition","year":"2011"},{"key":"10.1016\/j.ajpath.2018.03.018_bib33","doi-asserted-by":"crossref","first-page":"e0147212","DOI":"10.1371\/journal.pone.0147212","article-title":"Thalidomide improves the intestinal mucosal injury and suppresses mesenteric angiogenesis and vasodilatation by down-regulating inflammasomes-related cascades in cirrhotic rats","volume":"11","author":"Li","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.ajpath.2018.03.018_bib34","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/j.jhep.2014.05.049","article-title":"Long-term cannabinoid type 2 receptor agonist therapy decreases bacterial translocation in rats with cirrhosis and ascites","volume":"61","author":"Yang","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.ajpath.2018.03.018_bib35","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1039\/c3fo60036j","article-title":"Effect of polyunsaturated fatty acids on tight junctions in a model of the human intestinal epithelium under normal and inflammatory conditions","volume":"4","author":"Beguin","year":"2013","journal-title":"Food Funct"},{"key":"10.1016\/j.ajpath.2018.03.018_bib36","first-page":"G1010","article-title":"Hyperpermeability and ATP depletion induced by chronic hypoxia or glycolytic inhibition in Caco-2B Be monolayers","volume":"270","author":"Unno","year":"1996","journal-title":"Am J Physiol"},{"key":"10.1016\/j.ajpath.2018.03.018_bib37","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1002\/hep.1840090302","article-title":"Increased tumor necrosis factor production by monocytes in alcoholic hepatitis","volume":"9","author":"McClain","year":"1989","journal-title":"Hepatology"},{"key":"10.1016\/j.ajpath.2018.03.018_bib38","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1053\/gast.1996.v110.pm8608897","article-title":"Portal hypertension enhances endotoxin induced intercellular adhesion molecule 1 up-regulation in the rat","volume":"110","author":"Panes","year":"1996","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ajpath.2018.03.018_bib39","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/0016-5085(95)90449-2","article-title":"Tumor necrosis factor alpha: a major contributor to the hyperdynamic circulation in prehepatic portal-hypertensive rats","volume":"108","author":"Lopez-Talavera","year":"1995","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ajpath.2018.03.018_bib40","first-page":"104","article-title":"Tumor necrosis factor alpha signaling in the development of experimental murine pre-hepatic portal hypertension","volume":"2","author":"Theodorakis","year":"2010","journal-title":"Int J Physiol Pathophysiol Pharmacol"},{"key":"10.1016\/j.ajpath.2018.03.018_bib41","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/34178","article-title":"The peroxisome proliferator-activated receptor-\u03b3 is a negative regulator of macrophage activation","volume":"391","author":"Ricote","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.ajpath.2018.03.018_bib42","first-page":"243","article-title":"Effect of peroxisome proliferator-activated receptor activators on tumor necrosis factor-alpha expression in neonatal rat cardiac myocytes","volume":"19","author":"Ye","year":"2004","journal-title":"Chin Med Sci J"},{"key":"10.1016\/j.ajpath.2018.03.018_bib43","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.phrs.2016.02.027","article-title":"Therapeutic potential of the dual peroxisome proliferator activated receptor (PPAR) \u03b1\/\u03b3 agonist aleglitazar in attenuating TNF-\u03b1-mediated inflammation and insulin resistance in human adipocytes","volume":"107","author":"Massaro","year":"2016","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.ajpath.2018.03.018_bib44","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/S0140-6736(09)60870-9","article-title":"Effect of the dual peroxisome proliferator-activated receptor-alpha\/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study","volume":"374","author":"Henry","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.ajpath.2018.03.018_bib45","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1475-2840-10-7","article-title":"Effects of aleglitazar, a balanced dual peroxisome proliferator-activated receptor \u03b1\/\u03b3 agonist on glycemic and lipid parameters in a primate model of the metabolic syndrome","volume":"10","author":"Hansen","year":"2011","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.ajpath.2018.03.018_bib46","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1186\/1471-2369-15-180","article-title":"Effects of the dual peroxisome proliferator-activated receptor-\u03b1\/\u03b3 agonist aleglitazar on renal function in patients with stage 3 chronic kidney disease and type 2 diabetes: a phase IIb, randomized study","volume":"15","author":"Ruilope","year":"2000","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.ajpath.2018.03.018_bib47","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1177\/1479164116679081","article-title":"Aleglitazar, a dual peroxisome proliferator-activated receptor-\u03b1 and -\u03b3 agonist, protects cardiomyocytes against the adverse effects of hyperglycemia","volume":"14","author":"Chen","year":"2017","journal-title":"Diab Vasc Dis Res"},{"key":"10.1016\/j.ajpath.2018.03.018_bib48","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/dom.12006","article-title":"Effects of the dual PPAR-\u03b1\/\u03b3 agonist aleglitazar on glycaemic control and organ protection in the Zucker diabetic fatty rat","volume":"15","author":"B\u00e9nardeau","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.ajpath.2018.03.018_bib49","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.bbrc.2004.12.109","article-title":"TNF-alpha induces interleukin-8 and endothelin-1 expression in human endothelial cells with different redox pathways","volume":"327","author":"Zhao","year":"2005","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.ajpath.2018.03.018_bib50","first-page":"H7","article-title":"Endotoxin pretreatment enhances portal venous contractile response to endothelin-1","volume":"270","author":"Pannen","year":"1996","journal-title":"Am J Physiol"},{"key":"10.1016\/j.ajpath.2018.03.018_bib51","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1093\/clinchem\/46.12.2050","article-title":"Diagnosis and monitoring of hepatic injury, II: recommendations for use of laboratory tests in screening, diagnosis, and monitoring","volume":"46","author":"Dufour","year":"2000","journal-title":"Clin Chem"},{"key":"10.1016\/j.ajpath.2018.03.018_bib52","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s40291-013-0049-0","article-title":"Development of blood biomarkers for drug-induced liver injury, an evaluation of their potential for risk assessment and diagnostics","volume":"17","author":"Amacher","year":"2013","journal-title":"Mol Diagn Ther"},{"key":"10.1016\/j.ajpath.2018.03.018_bib53","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/hep.20772","article-title":"Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests","volume":"42","author":"Lok","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.ajpath.2018.03.018_bib54","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1172\/JCI105990","article-title":"Albumin synthesis in cirrhotic subjects with ascites studied with carbonate-14C","volume":"48","author":"Rothschild","year":"1969","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ajpath.2018.03.018_bib55","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1080\/00365520802530861","article-title":"Rosiglitazone prevents nutritional fibrosis and steatohepatitis in mice","volume":"44","author":"Nan","year":"2009","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.ajpath.2018.03.018_bib56","doi-asserted-by":"crossref","first-page":"e65251","DOI":"10.1371\/journal.pone.0065251","article-title":"Tumor necrosis factor-\u03b1 promotes cholestasis-induced liver fibrosis in the mouse through tissue inhibitor of metalloproteinase-1 production in hepatic stellate cells","volume":"8","author":"Osawa","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ajpath.2018.03.018_bib57","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.bbrc.2008.10.155","article-title":"TNF\u03b1 is required for cholestasis-induced liver fibrosis in the mouse","volume":"378","author":"G\u00e4bele","year":"2009","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.ajpath.2018.03.018_bib58","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1053\/jhep.2002.32524","article-title":"Hypoxia-induced VEGF and collagen I expressions are associated with angiogenesis and fibrogenesis in experimental cirrhosis","volume":"35","author":"Corpechot","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.ajpath.2018.03.018_bib59","doi-asserted-by":"crossref","first-page":"E94","DOI":"10.1111\/hepr.12732","article-title":"Intrahepatic angiogenesis increases portal hypertension in hepatitis B patients with cirrhosis","volume":"47","author":"Wang","year":"2017","journal-title":"Hepatol Res"},{"key":"10.1016\/j.ajpath.2018.03.018_bib60","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/1742-4682-4-44","article-title":"Inflammation: a way to understanding the evolution of portal hypertension","volume":"4","author":"Aller","year":"2007","journal-title":"Theor Biol Med Model"},{"key":"10.1016\/j.ajpath.2018.03.018_bib61","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1097\/MEG.0b013e32834a75dc","article-title":"Endotoxin and tumor necrosis factor-receptor levels in portal and hepatic vein of patients with alcoholic liver cirrhosis receiving elective transjugular intrahepatic portosystemic shunt","volume":"23","author":"Trebicka","year":"2011","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.ajpath.2018.03.018_bib62","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1152\/jappl.1993.75.6.2392","article-title":"Role of nitric oxide in effects of tumor necrosis factor-alpha on microcirculation in rat","volume":"75","author":"Baudry","year":"1993","journal-title":"J Appl Physiol"},{"key":"10.1016\/j.ajpath.2018.03.018_bib63","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1172\/JCI7458","article-title":"Bacterial translocation in cirrhotic rats stimulates eNOS-derived NO production and impairs mesenteric vascular contractility","volume":"104","author":"Wiest","year":"1999","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ajpath.2018.03.018_bib64","doi-asserted-by":"crossref","first-page":"e98016","DOI":"10.1371\/journal.pone.0098016","article-title":"Expressions of tight junction proteins Occludin and Claudin-1 are under the circadian control in the mouse large intestine: implications in intestinal permeability and susceptibility to colitis","volume":"9","author":"Kyoko","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ajpath.2018.03.018_bib65","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1093\/intimm\/dxu051","article-title":"Pleiotropic functions of TNF-alpha in the regulation of the intestinal epithelial response to inflammation","volume":"26","author":"Leppkes","year":"2014","journal-title":"Int Immunol"},{"key":"10.1016\/j.ajpath.2018.03.018_bib66","doi-asserted-by":"crossref","first-page":"G367","DOI":"10.1152\/ajpgi.00173.2003","article-title":"TNF-alpha-induced increase in intestinal epithelial tight junction permeability requires NF-kappa B activation","volume":"286","author":"Ma","year":"2004","journal-title":"Am J Physiol Gastrointest Liver Physiol"}],"updated-by":[{"DOI":"10.1016\/j.ajpath.2018.06.007","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000}}],"container-title":["The American Journal of Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000294401731057X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000294401731057X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,11,3]],"date-time":"2020-11-03T22:29:08Z","timestamp":1604442548000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000294401731057X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":66,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["S000294401731057X"],"URL":"https:\/\/doi.org\/10.1016\/j.ajpath.2018.03.018","relation":{"erratum":[{"id-type":"doi","id":"10.1016\/j.ajpath.2018.06.007","asserted-by":"object"}]},"ISSN":["0002-9440"],"issn-type":[{"value":"0002-9440","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Beneficial Effects of the Peroxisome Proliferator-Activated Receptor \u03b1\/\u03b3 Agonist Aleglitazar on Progressive Hepatic and Splanchnic Abnormalities in Cirrhotic Rats with Portal Hypertension","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajpath.2018.03.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 American Society for Investigative Pathology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}